Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The firm operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The company is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
3,349
3,349
3,156
2,875
2,517
2,553
Revenue Growth (YoY)
6%
6%
10%
14%
-1%
9%
Cost of Revenue
1,892
1,892
1,708
1,468
1,252
1,252
Gross Profit
1,457
1,457
1,448
1,407
1,265
1,301
Selling, General & Admin
566
566
568
544
509
488
Research & Development
151
151
141
149
144
143
Operating Expenses
779
715
819
785
756
742
Other Non Operating Income (Expenses)
71
--
-84
-14
-11
-13
Pretax Income
602
602
455
281
233
544
Income Tax Expense
112
112
93
89
42
124
Net Income
485
485
359
190
188
421
Net Income Growth
35%
35%
89%
1%
-55%
-2%
Shares Outstanding (Diluted)
222.93
222.68
223.49
222.36
225
233
Shares Change (YoY)
0%
0%
1%
-1%
-3%
-2%
EPS (Diluted)
2.18
2.18
1.61
0.85
0.84
1.81
EPS Growth
35%
35%
89%
1%
-54%
0%
Free Cash Flow
119
119
329
404
305
409
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
43.5%
43.5%
45.88%
48.93%
50.25%
50.95%
Operating Margin
20.24%
22.15%
19.93%
21.63%
20.22%
21.89%
Profit Margin
14.48%
14.48%
11.37%
6.6%
7.46%
16.49%
Free Cash Flow Margin
3.55%
3.55%
10.42%
14.05%
12.11%
16.02%
EBITDA
916
980
797
881
881
704
EBITDA Margin
27.35%
29.26%
25.25%
30.64%
35%
27.57%
D&A For EBITDA
238
238
168
259
372
145
EBIT
678
742
629
622
509
559
EBIT Margin
20.24%
22.15%
19.93%
21.63%
20.22%
21.89%
Effective Tax Rate
18.6%
18.6%
20.43%
31.67%
18.02%
22.79%
Follow-Up Questions
What are Hikma Pharmaceuticals PLC's key financial statements?
According to the latest financial statement (Form-10K), Hikma Pharmaceuticals PLC has a total asset of $5,671, Net profit of $485
What are the key financial ratios for HKMPF?
Hikma Pharmaceuticals PLC's Current ratio is 1.84, has a Net margin is 14.48, sales per share of $15.03.
How is Hikma Pharmaceuticals PLC's revenue broken down by segment or geography?
Hikma Pharmaceuticals PLC largest revenue segment is Injectables, at a revenue of 1,022,059,311 in the most earnings release.For geography, United States is the primary market for Hikma Pharmaceuticals PLC, at a revenue of 1,476,742,665.
Is Hikma Pharmaceuticals PLC profitable?
yes, according to the latest financial statements, Hikma Pharmaceuticals PLC has a net profit of $485
Does Hikma Pharmaceuticals PLC have any liabilities?
yes, Hikma Pharmaceuticals PLC has liability of 3,078
How many outstanding shares for Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC has a total outstanding shares of 221.88